Russ Conroy

Investigators plan to share data from the phase 3 KEYNOTE-671 trial assessing perioperative pembrolizumab in resectable non–small cell lung cancer with international regulatory health authorities.

A biologic license application supplement resubmission for the pegfilgrastim-cbqv on-body injector follows the resolution of inspection findings highlighted in a complete response letter from the FDA.

Investigators anticipate sharing final data from the phase 2 TELLOMAK trial assessing lacutamab among patients with cutaneous T-cell lymphoma in the fourth quarter of 2023.

Investigators report that MRI by itself seems to be an inadequate tool for determining pathologic complete response in rectal adenocarcinoma during total neoadjuvant therapy.

Investigators will continue to assess overall survival in patients treated with pembrolizumab for localized muscle-invasive urothelial carcinoma as part of the phase 3 AMBASSADOR trial.

Findings suggest that sensitive circulating tumor DNA analysis may be a valuable tool for guiding neoadjuvant treatment decision-making in early-stage triple-negative breast cancer.

Patients receiving ibrutinib plus venetoclax for chronic lymphocytic leukemia appear to experience improved overall survival at 46 months compared with those receiving chlorambucil plus obinutuzumab in the phase 3 GLOW study.

Complete responses in patients with pretreated relapsed/refractory mantle cell lymphoma treated with glofitamab appear to be early and enduring.

Combining pembrolizumab with enfortumab vedotin-ejfv significantly improves responses vs chemotherapy among patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Data from the phase 2 SGNTUC-019 study support HER2 as an actionable biomarker in patients with metastatic biliary tract cancer.

Findings from a meta-analysis support the feasibility of administering hysteroscopic surgery plus progesterone to patients of childbearing age with various types of endometrial cancer.

Investigators will present overall survival and objective response data from the phase 3 MARIPOSA-2 trial assessing amivantamab in EGFR exon 19 deletion–positive non–small cell lung cancer at a future scientific meeting.

Investigators are assessing AVB-001 as a treatment for those with high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube in a phase 1/2 trial.

Data from a phase 1 trial highlight a clinically acceptable safety profile for BI 764532 in patients with extensive-stage small cell lung cancer and extrapulmonary neuroendocrine carcinomas.

Patients with paroxysmal nocturnal hemoglobinuria can now self-administer pegcetacoplan subcutaneously following the FDA’s approval of an injector.

Data from the FABREC trial support the use of hypofractionated postmastectomy radiotherapy in patients with breast cancer following implant-based reconstruction.

Most adverse effects appear to be grade 1 or 2 among patients with hepatocellular carcinoma and other solid tumors associated with the MYC oncogene receiving OTX-2002 in the phase 1/2 MYCHELANGELO I trial.

Neeraj Agarwal, MD, states that he is optimistic about the development of new treatment options including immunotherapies, CAR T-cell therapies, and antibody-drug conjugates for metastatic prostate cancer.

APOBEC mutational activity appears to be prognostic in patients with newly diagnosed multiple myeloma or precursor diseases who receive daratumumab quadruplets, according to Kylee Maclachlan, MBChB, PhD.

Clearance of an automated immunoassay allows practices to measure chromogranin A concentration in human serum, thereby tracking disease progression in those with gastroenteropancreatic neuroendocrine tumors.

The FDA has not requested any additional data or clinical trials supporting the supplemental biologics license application for an on-body injector presentation of pegfilgrastim-cbqv.

Pembrolizumab plus lenvatinib does not improve objective response rate compared with standard-of-care treatment among patients with metastatic non–small cell lung cancer in the phase 3 LEAP-006 and LEAP-008 trials.

Community health worker–led intervention may yield improvements in patient activation, hospice use, and total health care costs compared with usual care in those with newly diagnosed cancer.

Findings from the PRO-TECT trial suggest that patients and nurses are generally in favor of implementing financial toxicity screening into routine care for cancer.

Data from the NeoRes II trial caution against routinely delaying surgery for more than 6 weeks after patients with resectable locally advanced esophageal cancer receive neoadjuvant chemoradiotherapy.

Treatment with ibrutinib significantly reduces the risk of initiating next treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared with bendamustine/rituximab in a real-world setting.

A health-related quality of life analysis of the phase 3 NATALEE trial supports the risk/benefit profile of adding ribociclib to nonsteroidal aromatase inhibitors in patients with hormone receptor–positive, HER2-negative early breast cancer.

Findings from a cross-sectional study support monitoring puberal development to estimate probabilities of future fertility among male childhood cancer survivors.

Data from the phase 3 ASCERTAIN trial support the European Commission’s approval of oral decitabine and cedazuridine as a treatment for those with newly diagnosed acute myeloid leukemia.

Findings from a meta-analysis indicate that interventions for caregivers of patients with advanced cancer may improve self-efficacy and grief.